Puncture liver biopsy-past or present?

The objective: To determine the diagnostic accuracy of non-invasive methods of diagnosis of liver fibrosis, as well as to analyze the interaction of laboratory parameters and the stage of liver fibrosis. Patients and methods. The work was performed in the infectious Department of 5 EKG of VNG of the Russian Federation in Yekaterinburg, 168 patients with CHC participated in the study. Before the administration of antiviral treatment to all CHC patients diagnosed with stage of liver fibrosis using three methods: needle biopsy of the liver, fibroelastometry and FibroTest. In the future, the sensitivity and specificity of non-invasive diagnostic methods depending on the stage of liver fibrosis were determined. Results. According to the results of liver puncture biopsy, patients with CHC depending on the stage of fibrosis were distributed as follows: with minimal fibrosis (F0-1) - 50.6% (85 people), moderate fibrosis (F2) - 25.6% (43 people), with severe fibrosis (F3) - 11.9% (20 people) and liver cirrhosis (F4) - 11.9% (20 people). According ROC curve analysis FibroTest highly informative only at the stage F4 fibrosis (AUROC=0,972), whereas fibroelastometry effective in severe F3 fibrosis (AUROC=0,847), and cirrhosis F4 the biopsies and elastography almost comparable (AUROC=0,994). In most patients with CGS at the stage of minimal and moderate fibrosis F≤2 it is advisable to use at least two non-invasive methods of diagnosis of liver fibrosis. Puncture liver biopsy is still a universal method of assessing the stage of liver fibrosis in patients with chronic viral infection. Conclusion. The sensitivity and specificity of noninvasive diagnostic methods for liver fibrosis in patients with CGS at stage F≤2 is unsatisfactory. In order to determine the true picture of the pathological process, a puncture liver biopsy is necessary.

фиброэластометрия, пункционная биопсия печени, фиброз печени, хронический гепатит С, Фибротест, fibroelastometry, liver biopsy, liver fibrosis, chronic hepatitis C, FibroTest

1. Губургриц Н. Б. Фиброз печени: от фатализма к оптимизму. / Н.Б. Губергриц, Г.М. Лукашевич, П.Г. Фоменко, Н.В. Беляева. - М.: Прима Принт, 2015. -18 с.

2. Ивашкин В.Т. Фиброз печени / В.Т. Ивашкин, Ч.С. Павлов - М.: ГЭОТАР-Медиа, 2011. - 168 с.

3. Патлусов Е.П. Клиническая и прогностическая оценка инвазивной и неинвазивных методик диагностики фиброза печени у больных хроническим гепатитом С: автореф. дисс.. канд.мед.наук. -Москва, 2018. - С.25.

4. Соболева Н.В. Распространенность вируса гепатита С среди условно здорового населения Российской Федерации /Н.В. Соболева, А.А. Карлсен, Т.В. Кожанова [и др.]// Журнал инфектологии. - 2017. - Т9, №2.- С.56-64. DOI: 10.22625/2072-6732-2017-9-2-56-64.

5. Чуланов В.П., Исаков В.А., Жданов К.В., Бакулин И.Г., Бурневич Э.З., Латарса-Смуга Д. Промежуточные результаты международного многоцентрового проспективного наблюдательного исследования «MOSAIC» по оценке эпидемиологии, субъективных и экономических исходов лечения хронического гепатита С. Инфекционные болезни. 2018; 16(1): 5-14. DOI: 10.20953/1729-9225-2018-1- 5-14.

6. Backus, L.I. A sustained virologie response reduces risk of all-cause mortality in patients with hepatitis C /L.I. Backus, R. Bartenschlaget; M. Frese, J. Halloran, L.A. Mole // Clin Gastroenterol Hepatol. 2011. - V 9, № 6. - P 509 - 516.

7. Beaugrand M. How to assess liver fibrosis and for what purpose?//J. of Hepatology. - 2006. - Vol.44, №3. -Р444-445.

8. Cipriano, L.E., Zaric, G.S., Holodniy, M., Bendavid, E., Owens, D.K., & Brandeau, M.L. Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. PLОS ONE, 2012.

9. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2016 Feb 1;62(3):298-304.

10. Van der Meer, A.J. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis / A.J. Van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour // JAMA. - 2012. - V. 308, № 24. - P. 2584 - 2593.

11. Global Burden of Disease Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.

12. Global policy report on the prevention and control of viral hepatitis in WHO Member States. Geneva: World Health Organization; 2013. (http://apps.who.int/iris/ bitstr eam/10665/85397/1/9789241564632_eng.pdf accessed 21 January 2014).

13. WHO. Global hepatitis report; 2017. 83 р.

14. WHO Representative Office Vietnam. Hepatitis C Fact sheet [Электронный ресурс]. - 2018. - Режим доступа:http://www.wpro.who.int/vietnam/topics/ hepatitis/factsheet_hepc/en/